Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-01-04
2011-01-04
Harris, Alana M (Department: 1643)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S004000, C435S007210, C436S063000, C436S064000, C436S174000
Reexamination Certificate
active
07863011
ABSTRACT:
A method to aid in identifying a familial or sporadic pattern of risk in at least one individual for developing cancer of a mucosal epithelial tissue, the method comprising screening said at least one individual for heterozygosity or homozygosity for a mutation in a gene coding for a Poly-Ig (Fc) receptor or a Poly-Ig-like (Fc) receptor capable of mediating inhibition of cancer cell growth by an immunoglobulin inhibitor. A method of treating an individual so identified includes enhancing the amount of immunoglobulin inhibitor contacting a mucosal epithelial tissue of said individual, and, especially in individuals homozygous for the defective receptor, may also include prophylactic surgery. Other methods include implementation of a risk reduction or prevention program in individuals identified as being at risk.
REFERENCES:
patent: 5405772 (1995-04-01), Ponting
patent: 6200547 (2001-03-01), Volkonsky et al.
patent: 2003/0017445 (2003-01-01), Berg et al.
patent: WO92/13563 (1992-08-01), None
patent: WO98/04681 (1998-02-01), None
patent: WO98/08934 (1998-03-01), None
Krajci et al. (Human Genetics 90: 215-219, 1992).
Kaiserlian et al. (The Journal of Immunology 135(2): 1126-1131, Aug. 1985).
Meric-Bernstam, Funda. Serum Proteomics for BRCA1-associated Breast Cancer. Annals of Surgical Oncology 11(10): 883-884, 2004.
Stern et al. Secretory component in breast cancer. Cancer Immunology Immunotherapy 19: 226-230, 1985.
PCT International Search Report, PCT/US01/15183 dated Nov. 20, 2002, 3 pages.
Zhihong Chen et al.,A serum-free medium for hybridoma cell culture, Cytotechnology (1993), vol. 11, pp. 169-174, XP001117870, ISSN: 0920-9069 p. 170, media and additives; pp. 173-174.
Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA US; 1992, Eby J.E. et al.,Preparation of Iron-Deficient Tissue Culture Medium by Deferoxamine-Sepharose Treatment and Application to the Differential Actions of Apotransferrin and Differic Transferrin, Database assession No. PREV199294057133, XP002218819 cited in the application abstract & Analytical Biochemistry, vol. 203, No. 2, 1992, pp. 317-325, ISSN:0003-2697.
Database Biosis 'Online! Biosciences Information Service, Philadelphia, PA US 1993, Eby John E. et al.,Apotransferrin stimulation of thyroid hormone dependent rat pituitary tumor cell growth in serum-free chemically defined medium: Role of iron(III)chelation, Database accession No. PREV199396113609, XP002218820 cited in application abstract & Journal of Cellular Physiology, vol. 156, No. 3, 1993, pp. 588-600, ISSN:0021-9541.
Neumannova Vera et al.,Growth of human tumor cell lines in transferrin-free, low-iron medium, In Vitro Cellular & Developmental Biology Animal, vol. 31, No. 8, 1995, pp. 625-632, XP001118629, ISSN:1071-2690, the whole document.
C.A. Janeway et al.,Chapter 3: Structure of the Antibody Molecule and the Immunoglobulin Genes: Structural variation in immunoglobulin constant regions; Chapter 9: The Humoral Immune Response: The distribution and functions of immunoglobulin isotypes, Immuno. Biology—The Immune System In Health and Disease, Fourth Edition, Elsevier Science Ltd./Garland Publishing (1999) pp. 104, 326-327.
R.G. Hamilton,Chapter 3: Human Immunoglobulins, Handbook of Human Immunology, CRC Press LLC (1997) pp. 65-109.
A.J. Alberg et al.,Epidemiology, prevention, and early detection of breast cancer [Breast], Current Opinion in Oncology (Nov. 1997) vol. 9, 6, pp. 505-511, PMID: 9370070 [PubMed—indexed for MEDLINE); Abstract http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=9370070&d... printed on Feb. 15, 2003 (1 page).
A.J. Alberg et al.,Epidemiology, prevention, and early detection of breast cancer [Breast], Current Opinion in Oncology (Nov. 1999) vol. 11, No. 6, pp. 435, 13 pages.
J.C. Allegra et al.,Growth of a Human Breast Cancer Cell Line in Serum-Free Hormone-Supplemented Medium, Cancer Research (Nov. 1978) vol. 38, pp. 3823-3829.
J.F. Amara et al.,17β—Estradiol Has a Biphasic Effect On GH Cell Growth, Endocrinology, Dept. of Pharm., Endocrinology (Mar. 1983) vol. 112, No. 3, pp. 1141-1143.
T. Anttila et al.,Serotypes of Chlamydia Trachomatis and Risk For Development of Cervical Squamous Cell Carcinoma, JAMA (Jan. 2001) vol. 285, No. 1, pp. 47-51, PMID: 11150108 [PubMed—indexed for MEDLINE); Abstract http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=11150108&d... printed on Feb. 15, 2003 (2 pages).
T. Anttila et al.,Serotypes of Chlamydia Trachomatis and Risk For Development of Cervical Squamous Cell Carcinoma, JAMA (Jan. 2001) vol. 285, No. 1, pp. 47-51, (Original Contribution) 11 pages.
J.M. Zenilman,Chlamydia and Cervical Cancer: A Real Association? JAMA (Jan. 2001) 285, No. 1, pp. 81-83, (Editorial) 5 pages.
P.E. Gravitt et al.,Chlamydia trachomatis and Cervical Squamous Cell Carcinoma, JAMA (Apr. 2001) vol. 285, No. 13, pp. 1703-1706, (Letters) 11 pages).
B.A. Arrick,Therapeutic implications of the TGF-beta system, J. Mammary Gland Biol. Neoplasia. (Oct. 1996) 1(4):391-7, PMID: 10887513 [PubMed—indexed for MEDLINE); Abstract http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=10887513&d... printed on Feb. 21, 2003 (1 page).
C.L. Arteaga et al.,Blockade of the Epidermal Growth Factor Receptor Inhibits Transforming Growth Factor α-Induced but Not Estrogen-Induced Growth of Hormone-Dependent Human Breast Cancer, Molecular Endocrinology (Nov. 1988) vol. 2, No. 1 pp. 1064-1069.
C.L. Arteaga et al.,Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice, J. Clin. Invest. (Nov. 1989) vol. 84, pp. 1418-1423.
C.L. Arteaga et al.,The multifunctional role of transforming growth factor(TGF)-beta s on mammary epithelial cell biology, Breast Cancer Res. Treat. 1996; 38(1):49-56, PMID: 8825122 [PubMed—indexed for MEDLINE]; Abstract; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=8825122&d... printed on Feb. 21, 2003 (1 page).
C.L. Arteaga et al.,Transforming Growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells, Breast Cancer Res Treat. (Jul. 1998) 48(14):3898-904, PMID: 3164252 [PubMed—indexed for MEDLINE]; Abstract; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=3164252&d... printed on Feb. 21, 2003 (2 pages).
A.M. Soto,The Role of Estrogens On The Proliferation of Human Breast Tumor Cells(MCF-7), J. Steroid Biochem. (1985) vol. 23, No. 1, pp. 87-94.
M.A. Bakos et al.,Expression and purification of biologically active domain I of the human polymeric immunoglobulin receptor, Mol. Immunol. (Feb. 1994) 31(2):165-8, PMID: 8309479 [PubMed—indexed for MEDLINE]; Abstract; http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=8309479&d... printed on Feb. 22, 2003, 1 page.
M.A. Bakos et al.,Characterization of a critical binding site for human polymeric Ig on secretory component, J. Immunol. (Nov. 1991) 147(10):3419-26, PMID: 1940346 [PubMed—indexed for MEDLINE]; Abstract Http://www.ncbi.nlm.nih,gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list—uids=1940346&d... printed on Feb. 20, 2003, 1 page.
M.A. Bakos et al.,A Conserved Binding Site on the Receptor for Polymeric Ig Is Homologous to CDRI of Ig Vk Domains, J. Immunol. (Aug. 1993) vol. 151, No. 3, pp. 1346-1352.
D. Barnes et al.,Growth of a human mammary tumour cell line in a serum-free medium, Nature, Macmillan Journals Ltd. (Oct. 1979) vol. 281, No. 5730, pp. 388-389.
J. Baselga et al.,Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2
eu-overexpressing metastatic breast cancer, Comment in J. Clin. Oncol. (Mar. 1996) vol. 14, No. 3, pp. 697-699, PMID: 8622019 [PubMed—indexed for MEDLINE]; Abstract, http://www.ncbi.nlm.nih.go
Harris Alana M
Signe Biopharma, Inc.
Woodard Emhardt Moriarty McNett & Henry LLP
LandOfFree
Screening method for predicting susceptibility to breast cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening method for predicting susceptibility to breast cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening method for predicting susceptibility to breast cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2739990